We propose a prospective observational analysis of near visual acuity and stereopsis in pseudophakic children. Visual acuity analysis will be standardized based on age per PEDIG protocols. Results will be stratified by age and by monocular versus binocular surgery. Children will be assessed in their appropriate corrective lenses to control for myopia as a confounding factor. Refractive error will be measured to optimize visual acuity measurement and assess for the potential role of astigmatism in preservation of near visual function.
Depression contributes directly to disability following a stroke and is the single strongest predictor of quality of life. Treatment of depressive symptoms is associated with better functional recovery and return to activities of daily living. Resistance training can effectively improve post-stroke mobility and has the potential to serve as an alternative (non-drug) anti-depressant treatment option. The purpose of this study is to assess the effects of resistance training on post-stroke depressive symptoms.
The purpose of this research study is to find out if a nerve block called the quadratus lumborum (QL) block can provide pain relief after hip replacement, similar to a lumbar plexus (LP) nerve block that we currently offer patients. There will be two groups in this study: one group will have the QL block placed and the other group will have the LP block placed.
This study is being done to determine if N-acetylcysteine (NAC) will reduce the amount of pain medications needed after some types of spinal surgeries.
Many children experience signs and/or symptoms of inflammation after cataract surgery. If left untreated, inflammation generally resolves within 2 to 4 weeks after surgery; however, inflammation can lead to complications without treatment. Doctors commonly use drugs, called corticosteroids, that are like the study product to reduce inflammation and the pain and discomfort it causes following cataract surgery. The purpose of this study is to compare the effects of DEXTENZA® to a drug already on the market (prednisolone acetate suspension) in treating the inflammation in the eye after cataract surgery. DEXTENZA® is an insertion and prednisolone acetate suspension is delivered as an eye drop. It is believed that DEXTENZA® may provide potential benefits because it requires only a single application by the physician at the time of cataract surgery. Eye drops are typically applied several times a day for several weeks.
Parkinson's disease and stroke can cause lasting changes in walking and mobility. Non-invasive brain imaging methods including Magnetic Resonance Imaging (MRI) have been useful tools to understand the brains contribution to disrupted gait. In this study we are evaluating how activity in the brain in stroke and Parkinson participants changes when they are engaged in a gait-like behavior in the MRI scanner. We are seeking to recruit 10 participants with a diagnosis of PD, 10 participants with a history of stroke, and 10 age matched healthy control participants without a diagnosis of PD to undergo an hour of MRI scanning and an hour of gait assessments.
NeuroDerm Ltd. has begun a study of an investigational drug (also known as an experimental drug and is being studied to see if a disease or medical condition improves while taking it) called ND0612 as a possible treatment for Parkinson's disease. ND0612 is a solution of levodopa/carbidopa (LD/CD) delivered as a continuous subcutaneous (SC, meaning under the skin) infusion through a pump system to treat Parkinson's disease.
The study is divided into 6 periods. Those periods are as follows:
- Screening Period: 1-4 weeks
- Adjustment Period: 4-6 weeks
- Conversion Period: 4-6 weeks
- Maintenance Period: 12 weeks
- Open-Label Treatment Extension Period: 12 months
- Safety Follow-Up Period: 1-3 months
Subjects will need to come to the study center at least 8 times, and an additional 7 times if he/she participates in the treatment extension period; in addition to visits to the study center, some visits/activities will be performed over the phone.
The infusion pump is worn and administered via 2 infusion sites: abdomen or outer thigh, with locations being changed on a daily basis.
This study will help to determine if UCB0599 (study drug) can slow the progression of Parkinson's Disease (PD.) The study will look to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage PD.
Study participation will take place over 19 months (16 Visits) and will consist of in-clinic and remote visits. Participants will take UCB0599 orally, in pill form.